All posts tagged: Nordisk

Ozempic Maker Novo Nordisk Confirms Security Incident After M Hacker Demand

Ozempic Maker Novo Nordisk Confirms Security Incident After $25M Hacker Demand

Published by Webster

A claimed breach at Novo Nordisk is putting more than patient privacy under the microscope. Hackers from FulcrumSec say they stole 1.3TB of data from the Danish pharmaceutical giant behind Ozempic and Wegovy after spending more than two months inside its systems, according to Reuters. Novo Nordisk has confirmed unauthorized access to a limited number of internal IT systems, but the full scope and authenticity of the hackers’ claims remain unverified. The incident points to a broader security problem for healthcare and pharmaceutical companies: clinical trial data, developer credentials, proprietary research, and internal AI assets are becoming prime targets. Hackers claim 1.3TB theft from Novo Nordisk after $25M demand According to Reuters, FulcrumSec claimed it spent more than two months inside Novo Nordisk’s networks and was exploring private sales of some stolen data after the company refused to pay $25 million. Reuters said it could not immediately verify the authenticity of the data posted by the group. Novo Nordisk said in its incident update that it had identified “unauthorised access to a limited number of …

Why Novo Nordisk Moved Delhi HC Against DRL

Why Novo Nordisk Moved Delhi HC Against DRL

Published by Parlour News

Novo Nordisk is fighting tooth and nail to protect its blockbuster semaglutide product, branded as Ozempic for weight loss/obesity and WeGovy for type-2 diabetes treatment. The Danish pharma giant has filed a number of lawsuits alleging patent infringement against several Indian generic companies, with no success. Now, it has moved a suit at the Delhi High Court against Indian generic drug maker Dr Reddy’s Laboratories (DRL), accusing it of infringing on its ‘Ozempic’ trademark. The reason? The DRL product was called ‘Olymviq’. On Wednesday, DRL conceded and assured the court that it would maintain status quo on any further manufacturing or market release under the brand name ‘Olymviq’. What was the product launched by Dr Reddy’s called? DRL, on March 21, announced the launch of the semaglutide formulation under the brand name ‘Obeda’,  to be used for treating type-2 diabetes. What it did not announce, however, was that it planned to release the drug under two other brand names — Olymviq and Mashlo. Trademark registry records show that DRL first applied for the ‘Olymviq’ trademark …

Novo Nordisk cuts price of its weight loss drug by 37% | India News

Novo Nordisk cuts price of its weight loss drug by 37% | India News

Published by Parlour News

Pharmaceutical giant Novo Nordisk on Tuesday dropped the price of its popular weight loss drug by 37% — from a weekly price of Rs 4,336 to Rs 2,712 for its lowest 0.25 mg dose. The highest 2.4 mg dose of Wegovy will now be priced at Rs 4,100 a week, making the drug significantly cheaper than its competitor Eli Lilly’s Mounjaro. The price drop comes at a time when Eli Lilly has been steadily capturing the weight loss market in India, entering the market months before Novo Nordisk. Mounjaro is priced at Rs 3,500 per 2.5 mg single-dose vial and Rs 4,375 per 5 mg single-dose vial, adding up to anywhere between Rs 14,000 to Rs 17,500 a month. When it comes to its easy use KwikPen, the highest 15 mg dose is available at the cost of Rs 27,500 per month. The monthly sales of Mounjaro is almost ten fold that of Wegovy in India in October. It also became the top-selling drug by value, with sales of around Rs 100 crore in October, …

Novo Nordisk to phase out human insulin pens globally: Will it disrupt your dosage? | Health and Wellness News

Novo Nordisk to phase out human insulin pens globally: Will it disrupt your dosage? | Health and Wellness News

Published by Parlour News

Thirty-seven-year-old Nupur Lalvani, who has been living with Type 1 diabetes since the age of eight, was dependent on insulin pens and had of late been a regular user of Novo Nordisk’s largest insulin brand, Human Mixtard. But now that the Danish major is phasing it out, the move is expected to disrupt Indian markets, where it is the largest seller, and affect patients like Lalvani. As founder of Blue Circle Diabetes Foundation – among the largest patient-led communities for all types of diabetes – she has flagged concerns about changes in the insulin portfolio. “Doctors say alternative brands are available. Switching brands and delivery devices is not a seamless process, especially for those managing diabetes every day on tight budgets,” she says. As per an ICMR-INDIAB study, around 11 million individuals with diabetes are on insulin. What is the pen all about? It is a pre-filled insulin pen containing insulin aspart, a fast-acting insulin analog. It helps glucose get into cells for energy, lowering blood sugar levels. It should be taken at the start …